What is the appropriate treatment plan for a patient with Epstein‑Barr virus viral capsid antigen (VCA) IgG positivity?

EBV VCA-IgG Positivity Alone Does NOT Require Treatment

If you have only positive EBV VCA-IgG without symptoms, this indicates past infection and immunity—no treatment is needed. Over 95% of adults worldwide are EBV VCA-IgG positive, representing resolved infection with lifelong viral carriage 1.

Clinical Decision Algorithm

Step 1: Determine Clinical Context

Asymptomatic with isolated VCA-IgG positive:

• This is normal serology indicating past EBV exposure
• No intervention required
• No follow-up testing needed

Symptomatic patients require further evaluation:

Step 2: If Symptomatic, Assess for Chronic Active EBV Disease (CAEBV)

CAEBV diagnosis requires ALL three criteria 2:

1. Persistent/recurrent infectious mononucleosis-like symptoms:

   • Fever (prolonged or intermittent)
   • Lymphadenopathy and/or hepatosplenomegaly
   • Severe fatigue, sore throat, headache, myalgia
   • Complications: hematologic abnormalities, cardiovascular disorders (coronary aneurysms, valvular disease), neurological symptoms

2. Abnormal EBV serology PLUS high viral load:

   • VCA-IgG ≥1:640 (not just positive)
   • EA-IgG ≥1:160
   • EBV DNA ≥10,000 IU/mL in whole blood 2
   • Confirmation of EBV-infected T or NK cells (not B cells)

3. No other disease explanation

Step 3: Treatment Based on Diagnosis

For typical VCA-IgG positivity (past infection):

• No treatment indicated

For acute infectious mononucleosis:

• Supportive care only
• Acyclovir has minimal clinical benefit despite reducing viral shedding 3
• Avoid antivirals in routine cases

For confirmed CAEBV (meeting all diagnostic criteria):

Hematopoietic stem cell transplantation (HSCT) is the ONLY curative treatment 2, 4. The treatment algorithm is:

1. Immediate disease control with chemotherapy before HSCT 2

   • Options include prednisolone, cyclosporine A, with or without etoposide 4
   • Goal: reduce disease activity and prevent fatal hypercytokinemia/hemophagocytic syndrome

2. Proceed to allogeneic HSCT as soon as feasible 4

   • 3-year overall survival: 87.3% with planned HSCT
   • 3-year overall survival: only 16.7% with uncontrolled disease
   • Do not adopt "watchful waiting"—earlier HSCT improves outcomes 4

3. Avoid delays: Patients can develop sudden severe hypercytokinemia and hemophagocytic syndrome leading to death within years without HSCT 4

Critical Pitfalls to Avoid

• Do not treat isolated VCA-IgG positivity: This represents normal immunity in 95% of the population
• Do not confuse past infection with active disease: CAEBV requires very high titers (VCA-IgG ≥1:640), high viral load (≥10,000 IU/mL), AND persistent symptoms 5, 2
• Do not use antivirals for routine EBV: Acyclovir and valganciclovir have no established role in CAEBV or typical EBV infection 3, 1
• Do not delay HSCT in confirmed CAEBV: This is uniformly fatal without transplantation; earlier intervention dramatically improves survival 4

When Antiviral Therapy Might Be Considered

The evidence for antivirals is weak, but valganciclovir has been studied in chronic fatigue syndrome patients with elevated EBV titers, showing subjective improvement 6. However, this is NOT standard care for CAEBV, and HSCT remains the definitive treatment for true CAEBV.

For immunocompromised patients with EBV-associated lymphoproliferative disorders (PTLD), chemotherapy or radiation is recommended, not antivirals 3, 1.